title: Post-triptan era for the treatment of acute migraine.
abstract: There now is one realized and several attractive targets for the treatment of acute attacks of migraine that will follow and augment the use of serotonin 5-HT1B/1D receptor agonists, the triptans. Calcitonin gene-related peptide (CGRP) receptor blockade recently has been shown to be an effective acute antimigraine strategy; therefore, blockade of CGRP release by inhibition of trigeminal nerves would seem a logical approach. A number of targets are reviewed in this article including serotonin 5-HT1F and 5-HT1D receptors, adenosine A1 receptors, nociceptin, vanilloid TRPV1 receptors, and anandamide CB1 receptors. Development of one or more such compound offers the exciting prospect of new non-vasoconstrictor treatments for migraine and cluster headache.
authors.affiliation: Institute of Neurology, Queen Square, London WC1N 3BG, UK. peterg@ion.ucl.ac.uk
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Goadsby
mesh_terms: D000208:Acute Disease; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D002211:Capsaicin / Q000494:pharmacology* / Q000627:therapeutic use*; D003027:Cluster Headache / Q000188:drug therapy; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D018847:Opioid Peptides / Q000494:pharmacology* / Q000627:therapeutic use*; D043682:Receptor, Adenosine A1 / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology* / Q000627:therapeutic use*; D014276:Trigeminal Nerve / Q000187:drug effects*; D014364:Tryptophan / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000097629:Nociceptin
chemical_list: D018687:Antidepressive Agents, Second-Generation; D002211:Capsaicin; D018847:Opioid Peptides; D043682:Receptor, Adenosine A1; D017366:Serotonin Receptor Agonists; D014364:Tryptophan; D014665:Vasodilator Agents; D000097629:Nociceptin